Celon Pharma S.A.

Celon Pharma S.A. is European clinical-stage and commercial biopharmaceutical company founded in 2002 and listed on the Warsaw Stock Exchange (WSE: CLN). We hope to improve the lives of people suffering from neurological, metabolic, anti-inflammatory, and oncological diseases by developing novel therapies using sophisticated technologies such as mRNA and bispecifics. We have built a highly experienced 220-scientist team of seasoned leaders and drug developers who combine a nimble, results-driven mindset with expertise in clinical design and execution as well as drug discovery and development located in the complex state-of-the-art R&D facility. Our clinical and preclinical pipeline includes wholly-owned therapeutic candidates targeting difficult-to-treat cancers, autoimmune diseases, and other serious diseases. With our unique heritage, we are powered to advance our 16 active research and development programs out of which 5 are currently in clinical development. Celon currently implements 16 of innovative research projects in these areas, 5 of which are in the clinical phase. Celon’s most advanced programs are the Falkieri program concerning the use of esketamine in the treatment of drug-resistant depression, bipolar affective disorder, the CPL’36 program concerning the use of the PDE10a inhibitor in the treatment of schizophrenia and psychomotor disorders, the CPL’110 program concerning the use of the FGFR inhibitor in the treatment of solid tumors (bladder, lung, gastric), and the CPL’280 program concerning the use of the GPR40 agonist in the treatment of diabetes and diabetic neuropathy. We develop our innovative programs with respect to the requirements of global Regulatory Authorities. We are resource- and capital-efficient in the development of our therapeutic candidates by revenues from well-developed generics sales and heavily co-financing by European Union non-refundable grants.

Discover our innovative pipeline: https://www.youtube.com/watch?v=Imbt3ETDKjk

Celon’s research and development model is based on fully integrated in-house capabilities, starting from the development of a drug idea to manufacturing for the purposes of clinical trials. Celon develops innovative projects until Phase II clinical trials with the aim of finding a partner for Phase III and out-licensing the sale of a drug.

We would like to present to potential partners our clinical innovative assets, our preclinical programs and mRNA platform.

We are also seeking new interested investors.